Payment overview · 2025
General Payments
$524.65
13 reported records · 6 companies
Healthcare provider profile · identity verified
Lorenzo Munoz, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PINELLAS PARK, FL · NPI 1124014766
Verified facts
What the public records show
CMS Open Payments records show Lorenzo Munoz, M.D. received $524.65 in general payments during 2025 across 13 reported records.
AstraZeneca Pharmaceuticals LP accounted for 63.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $334.28 | 63.7% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $88.19 | 16.8% | 1 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $34.56 | 6.6% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $28.72 | 5.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.51 | 3.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.39 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $524.65 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $182.40 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $110.23 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $88.19 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $41.65 | 2 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $34.56 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $28.72 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $28.72 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $19.51 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $19.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
29 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
105 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 987 | 360 |
| Lisinopril | Lisinopril | 537 | 193 |
| Losartan Potassium | Losartan Potassium | 512 | 183 |
| Metformin Hcl | Metformin Hcl | 428 | 170 |
| Levothyroxine Sodium | Levothyroxine Sodium | 394 | 142 |
| Amlodipine Besylate | Amlodipine Besylate | 382 | 151 |
| Glipizide | Glipizide | 267 | 89 |
| Sertraline Hcl | Sertraline Hcl | 250 | 96 |
| Omeprazole | Omeprazole | 247 | 103 |
| Tamsulosin Hcl | Tamsulosin Hcl | 214 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 212 | 90 |
| Trazodone Hcl | Trazodone Hcl | 202 | 87 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 201 | 74 |
| Fluticasone Propionate | Fluticasone Propionate | 201 | 84 |
| Gabapentin | Gabapentin | 195 | 83 |
| Montelukast Sodium | Montelukast Sodium | 193 | 80 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 187 | 71 |
| Tramadol Hcl | Tramadol Hcl | 186 | 77 |
| Metoprolol Tartrate | Metoprolol Tartrate | 179 | 72 |
| Hydrochlorothiazide | Hydrochlorothiazide | 142 | 52 |
| Famotidine | Famotidine | 139 | 60 |
| Methocarbamol | Methocarbamol | 136 | 69 |
| Simvastatin | Simvastatin | 129 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 124 | 49 |
| Alendronate Sodium | Alendronate Sodium | 123 | 42 |
| Furosemide | Furosemide | 119 | 48 |
| Alprazolam | Alprazolam | 105 | 40 |
| Eliquis | Apixaban | 105 | 30 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 102 | 83 |
| Carvedilol | Carvedilol | 99 | 35 |
| Azithromycin | Azithromycin | 88 | 82 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 37 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 86 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 85 | 39 |
| Ondansetron Hcl | Ondansetron Hcl | 71 | 41 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 68 | 20 |
| Finasteride | Finasteride | 68 | 25 |
| Oxybutynin Chloride | Oxybutynin Chloride | 67 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 62 | 33 |
| Clobetasol Propionate | Clobetasol Propionate | 60 | 35 |
| Atenolol | Atenolol | 59 | 19 |
| Chlorthalidone | Chlorthalidone | 59 | 21 |
| Clonazepam | Clonazepam | 59 | 20 |
| Latanoprost | Latanoprost | 57 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 20 |
| Prednisone | Prednisone | 57 | 43 |
| Allopurinol | Allopurinol | 55 | 21 |
| Clonidine Hcl | Clonidine Hcl | 49 | 19 |
| Lorazepam | Lorazepam | 49 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | 20 |
| Memantine Hcl | Memantine Hcl | 46 | 24 |
| Potassium Chloride | Potassium Chloride | 46 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 18 |
| Sildenafil Citrate | Sildenafil Citrate | 44 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 15 |
| Xarelto | Rivaroxaban | 42 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 18 |
| Temazepam | Temazepam | 41 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 40 | 26 |
| Nitroglycerin | Nitroglycerin | 40 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | 13 |
| Ketoconazole | Ketoconazole | 38 | 28 |
| Valsartan | Valsartan | 38 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | 14 |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 36 | suppressed |
| Acyclovir | Acyclovir | 35 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | 14 |
| Levofloxacin | Levofloxacin | 34 | 28 |
| Tresiba Flextouch U-100 | Insulin Degludec | 34 | suppressed |
| Ozempic | Semaglutide | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 31 | 13 |
| Mupirocin | Mupirocin | 31 | 24 |
| Novolin R | Insulin Regular, Human | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 27 |
| Testosterone Cypionate | Testosterone Cypionate | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | 13 |
| Meloxicam | Meloxicam | 29 | 14 |
| Pregabalin | Pregabalin | 29 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | 11 |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Ezetimibe | Ezetimibe | 26 | 12 |
| Glimepiride | Glimepiride | 26 | 12 |
| Lactulose | Lactulose | 26 | 17 |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Tresiba | Insulin Degludec | 24 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 23 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 23 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | 11 |
| Topiramate | Topiramate | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Loperamide | Loperamide Hcl | 22 | 11 |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 19 |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Baclofen | Baclofen | 20 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 12 |
| Glipizide Er | Glipizide | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Timolol Maleate | Timolol Maleate | 18 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Jardiance | Empagliflozin | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 16 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 13 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 13 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Restasis | Cyclosporine | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Procto-Med Hc | Hydrocortisone | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | 11 |
| Permethrin | Permethrin | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $524.65 · 13 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AURYON LASER SYSTEM 100-120 VAC, BREZTRI, FARXIGA, KISUNLA, NURTEC ODT, Natroba, REPATHA, Spinosad | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error